Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

DUZALLO

ALLOPURINOL; LESINURAD

Standard Dose
300MG;200MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview DUZALLO is listed in Drugs@FDA under application 209203 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ALLOPURINOL; LESINURAD Form and strength TABLET;ORAL - 300MG;200MG Sponsor IRONWOOD PHARMS INC Submission history Latest submission status date: 2017-08-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview DUZALLO is listed in Drugs@FDA under application 209203 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ALLOPURINOL; LESINURAD Form and strength TABLET;ORAL - 300MG;200MG Sponsor IRONWOOD PHARMS INC Submission history Latest submission status date: 2017-08-18 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.